ARTICLE | Clinical News
SYN-010: Phase II started
July 20, 2015 7:00 AM UTC
Synthetic began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 21 and 42 mg oral SYN-010 once daily for 28 days in about 60 breath methane-positive patients. Synthetic is developi...